close

Agreements

1 2 3 229
Number of results: 4570

Excel print is not allowed for data more than 3000.Please search above for fewer data.

Date Company Compound Disease Type of agreement Therapeutic area Type of Information
2018-02-20 Voyager Therapeutics (USA - MA) Abbvie (USA - IL) vectorized antibodies directed against tau Alzheimer’s disease and other tau-related neurodegenerative diseases development - commercialisation Neurodegenerative diseases Development agreement
2018-02-15 Oxford Biomedica (UK) Bioverativ (USA - CA) lentiviral vectors to treat haemophilia hemophilia licensing - collaboration Rare diseases - Genetic diseases - Hematological diseases Licensing agreement
2018-02-05 Orchard Therapeutics (UK) member of the scientific advisory board nomination Rare diseases - Genetic diseases Nomination
2018-02-05 Oryzon Genomics (Spain) member of the scientific advisory board nomination Cancer - Oncology - Neurodegenerative diseases Nomination
2018-01-25 Synpromics (UK) UCL Great Ormond Street Institute of Child Health (UK) synthetic tissue-specific promoters for use in the specialised cells of the immune system pathologies affecting the haematopoietic system research - development Cancer - Oncology - Immunological diseases Development agreement
2018-01-22 Sillajen (Republic of Korea) ABL Europe (France) Pexa-Vec (formerly JX-594), JX-970 production - manufacturing Technology - Services - Cancer - Oncology Production agreement
2018-01-18 Gilead Sciences (USA - CA) Pfizer (USA - NY) Yescarta™ (axicabtagene ciloleucel) and utomilumab large B-cell lymphoma refractory large B-cell lymphoma clinical research Cancer - Oncology Clinical research agreement
2018-01-17 Homology Medicines (USA - MA) member of the board of directors nomination Rare diseases - Genetic diseases Nomination
2018-01-10 Ipsen (France) vice-president nomination Cancer - Oncology - Rare diseases - Neurological diseases Nomination
2018-01-10 Aimmune Therapeutics (USA - CA) Archer Daniels Midland (USA -IL) peanuts and tree nuts and exclusively supplies the starting material for AR101 peanut allergy production - manufacturing   Allergic diseases Production agreement
2018-01-10 Basilea Pharmaceutica (Switzerland) Pfizer (USA - NY) Cresemba® (isavuconazole) life-threatening invasive mold infections licensing Infectious diseases Licensing agreement
2018-01-08 Sanofi (France) Regeneron Pharmaceuticals (USA - NY) bispecific antibodies and monoclonal antibodies including REGN3500, dupilumab and programmed cell death protein 1 (PD-1) inhibitor cemiplimab collaboration - development - commercialisation Allergic diseases - Cancer - Oncology Collaboration agreement
2018-01-08 Five Prime Therapeutics (USA - CA) BMS (USA - NY) immuno-oncology therapies directed toward targets in three undisclosed immune checkpoint pathways R&D - development - commercialisation Cancer - Oncology Milestone
2018-01-08 GSK (UK) Regeneron Pharmaceuticals (USA - NY) UK Biobank (UK) IBM Watson Health (USA) Abbvie (USA - IL) Alnylam Pharmaceuticals (USA - MA) AstraZEneca (UK) Biogen (USA - MA) Pfizer (USA - NY) genetic exome sequence data collaboration - research Technology - Services Collaboration agreement
2018-01-08 Innate Pharma (France) chief scientific officer nomination Cancer - Oncology - Immunological diseases Nomination
2018-01-08 Heidelberg Pharma (Germany) Advanced Proteome Therapeutics (Canada) antibody-drug conjugates (ADCs) collaboration Cancer - Oncology Milestone
2018-01-08 Adaptimmune (UK) Cell and Gene Therapy Catapult (UK) SPEAR T-cell therapies production - manufacturing Technology - Services Production agreement
2018-01-08 Bioaster (France) Sanofi Pasteur (France) MOSAIC (MOlecular Signatures of Adjuvanted vaccIne Candidates) project collaboration - research Infectious diseases Collaboration agreement
2018-01-07 Genzyme (USA - MA), a Sanofi company (France) - Alnylam Pharmaceuticals (USA - MA) RNAi therapeutics including ALN-AT3, fitusiran, patisiran and ALN-TTRsc02 rare genetic diseases including hemophilia A, hemophilia B development - commercialisation Rare diseases - Genetic diseases Development agreement
2018-01-05 Takeda Pharmaceutical (Japan) Denali Therapeutics (USA - CA) up to three specified therapeutic product candidates for neurodegenerative diseases neurodegenerative disorders, including Alzheimer’s disease and other indications collaboration - development - commercialisation Neurodegenerative diseases Development agreement